ADPT (Adaptive Biotechnologies) Research & Development: $93.2 Mil (TTM As of Mar. 2026)


ADPT Adaptive Biotechnologies Corp ADPT
67 GF Score
Price $19.73
GF Value $10.06
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Adaptive Biotechnologies Research & Development?

Adaptive Biotechnologies ADPT +1.99% 67 Research & Development is $93.2 Mil as of Mar. 2026. GuruFocus rates ADPT with a GF Score™ of 67/100 and a GF Value™ of $10.06 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Adaptive Biotechnologies's Research & Development for the three months ended in Mar. 2026 was $23.6 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $93.2 Mil.

Adaptive Biotechnologies  (NAS:ADPT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Adaptive Biotechnologies Research & Development Related Terms

Adaptive Biotechnologies Research & Development Historical Data

* Premium members only.

The historical data trend for Adaptive Biotechnologies's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptive Biotechnologies Research & Development Chart

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 142.34 141.76 122.12 102.95 93.77

Adaptive Biotechnologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.20 24.13 23.67 21.76 23.62
ADPT
67GF Score
Adaptive Biotechnologies Corp ADPT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adaptive Biotechnologies Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $93.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $93.2 Mil mean?
Adaptive Biotechnologies (ADPT) has a Research & Development of $93.2 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Adaptive Biotechnologies and its competitors.
Is Adaptive Biotechnologies' Research & Development too high?
Adaptive Biotechnologies' current Research & Development is $93.2 Mil. Overall, Adaptive Biotechnologies has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' Research & Development compare to GRAL and WGS?
Adaptive Biotechnologies' Research & Development of $93.2 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Adaptive Biotechnologies and its competitors. Adaptive Biotechnologies's current Research & Development is $93.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.06, compared to a current price of $19.73 — trading 96.1% above its estimated fair value. The current Research & Development is $93.2 Mil. Adaptive Biotechnologies' overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current Research & Development is $93.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of $19.73 is trading 96.1% above its estimated GF Value™ of $10.06. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for ADPT:

  • Research & Development: $93.2 Mil
  • GF Value™: $10.06 vs. price of $19.73 (96.1% above fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adaptive Biotechnologies Business Description

Other Exchanges 1HM:Germany
Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
67GF Score

Get the complete analysis for ADPT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.73
Price
$10.06
GF Value